John Cox - Mar 25, 2024 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Chief Executive Officer and President, Director
Signature
/s/ Richard Scalzo, Attorney-in-Fact
Stock symbol
DYN
Transactions as of
Mar 25, 2024
Transactions value $
$0
Form type
4
Date filed
3/27/2024, 04:24 PM
Previous filing
Aug 11, 2023
Next filing
Sep 4, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock Option (Right to Buy) Award $0 +680K $0.00 680K Mar 25, 2024 Common Stock 680K $26.06 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on March 25, 2024. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 25, 2025, and the remainder vesting in equal monthly installments thereafter, subject to continuous service

Remarks:

Chief Executive Officer and President